For research use only. Not for therapeutic Use.
STL1267 is a potent and cross-the-blood-brain barrier REV-ERB agonist with a Ki value of 0.16 µM for REV-ERBα. STL1267 shows no cytotoxicity. STL1267 inhibits the gene expression of BMAL1[1].
STL1267 (5 µM; 24 h) decreases the expression of BMAL1 and increases the gene expression of Mtnd1, Mtco1, Vicad, Lcad, Scad, Lkb1, Sirt1, Nampt, Ppargc1a in HepG2 cells[1].
STL1267 (50 mg/kg; i.p.; once) inhibits Bmal1 expression in mouse[1].
| Catalog Number | I041985 |
| CAS Number | 1429024-58-7 |
| Synonyms | 3-chloro-6-(2-phenylphenoxy)-[1,2,4]triazolo[4,3-b]pyridazine |
| Molecular Formula | C17H11ClN4O |
| Purity | ≥95% |
| InChI | InChI=1S/C17H11ClN4O/c18-17-20-19-15-10-11-16(21-22(15)17)23-14-9-5-4-8-13(14)12-6-2-1-3-7-12/h1-11H |
| InChIKey | XWHTYUYQMHCFMT-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)C2=CC=CC=C2OC3=NN4C(=NN=C4Cl)C=C3 |
| Reference | [1]. Murray MH, et al. Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB. Nat Commun. 2022 Nov 21;13(1):7131. |
